AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsTechnology, Industry, AgricultureInformation ScienceHealth Care
StentsDrug-Eluting StentsCoronary RestenosisSirolimusAngioplasty, Balloon, CoronaryProsthesis DesignMetalsAlloysCoated Materials, BiocompatiblePaclitaxelCoronary ThrombosisTreatment OutcomeCardiovascular AgentsCoronary AngiographyCoronary StenosisCoronary Artery DiseaseAbsorbable ImplantsCoronary VesselsFollow-Up StudiesThrombosisUltrasonography, InterventionalGraft Occlusion, VascularStainless SteelDrug ImplantsTubulin ModulatorsAngioplasty, BalloonConstriction, PathologicMyocardial InfarctionImmunosuppressive AgentsNeointimaIliac ArteryPlatelet Aggregation InhibitorsTunica IntimaPercutaneous Coronary InterventionChromium AlloysPolymersTime FactorsEquipment DesignRetreatmentBlood Vessel ProsthesisBlood Vessel Prosthesis ImplantationHyperplasiaCoronary DiseaseVascular PatencyRegistriesMyocardial RevascularizationTracheal StenosisEsophageal StenosisRecurrenceRetrospective StudiesDrug Delivery SystemsProsthesis FailureCatheterizationAngioplastyTiclopidineProspective StudiesKaplan-Meier EstimateArterial Occlusive DiseasesForeign-Body MigrationPlasticsProsthesis ImplantationEquipment FailureCoronary OcclusionRandomized Controlled Trials as TopicPalliative CareGastric Outlet ObstructionSwineDevice RemovalRisk AssessmentAspirinFemoral ArteryPolytetrafluoroethyleneSwine, MiniatureAngiographyCoronary Artery BypassRisk FactorsForeign-Body ReactionIntubationUreteral DiseasesAngioscopyEquipment Failure AnalysisFeasibility StudiesPropensity ScoreSiliconesRadiology, InterventionalBiodegradable PlasticsPostoperative ComplicationsDiabetic AngiopathiesJaundice, ObstructiveDuodenal ObstructionUreterCholangiopancreatography, Endoscopic RetrogradeProportional Hazards ModelsPopliteal ArteryBeta ParticlesIntracranial AneurysmChi-Square DistributionTomography, Optical CoherenceBrachytherapySaphenous Vein
ThrombosisRestenosisPercutaneousLesionUnderwentRevascularization With Drug-ElutinMetal stentsSirolimus-elutiPaclitaxel-elutiStenosisDiabetic patientsLesionsBareClopidogrelMethodsDiabetesAngioplastyDual-antiplatelet therapyOutcomeEfficacyMyocardialPlacementAngiographicVersusAntiplatelet therapyBioabsorbableNeointimal hyperplasiaCYPHERTAXUSTherapyTreatment of coronaryAcuteInterventionRegistryOptical CoherenceAspirinVesselScaffoldsTotal occlusionCardiovascularCommercializationMortalityLong-termTrialsMalappositionRandomly assigned to eitherResults
Thrombosis14
  • Several concerns have emerged regarding the higher risk for stent thrombosis (ST) after drug-eluting stent (DES) implantation, especially in the setting of ST-segment elevation myocardial infarction (STEMI). (mssm.edu)
  • Newer scientific research have shown that even though associated with a lower rate of re-stenosis, first-generation drug eluting stents (DES) were associated with a higher rate of late stent thrombosis. (biomedcentral.com)
  • Similarly, risks of target lesion revascularization (OR: 1.09, 95% CI: 0.77 to 1.54, p = 0.62), target vessel revascularization (OR: 0.88, 95% CI: 0.63 to 1.22, p = 0.43), and definite or probable stent thrombosis (OR: 0.73, 95% CI: 0.38 to 1.38, p = 0.33) were comparable for women and men. (ox.ac.uk)
  • Additionally, the primary safety measure of major adverse cardiovascular events (MACE), including death, reinfarction, stent thrombosis and stroke established the superiority of drug-eluting stents with respect to safety through one year. (dotmed.com)
  • Long stenting was associated with a higher risk of early stent thrombosis (log-rank p=0.001), but not with that of late stent thrombosis (log-rank p=0.887). (pcronline.com)
  • In the contemporary second-generation DES era, stenting longer than 40 mm continues to be associated with less favourable clinical outcomes such as TLF and stent thrombosis. (pcronline.com)
  • And of the nine stents that fractured most severely, 67 percent showed signs of thrombosis (blood clots), restenosis (scar tissue) or other adverse conditions. (massdevice.com)
  • Mortality, major adverse cardiovascular events (MACEs), target vessel failure, and stent thrombosis (ST) occur more frequently as the result of calcium-mediated poor lesion preparation, stent under expansion, and stent malapposition ( 2 ). (frontiersin.org)
  • 64-slice multidetector CT (MDCT) coronary angiography has been shown to detect poststent complications such as instent stenosis, thrombosis, stent migration and stent fractures. (hindawi.com)
  • We report a case of stent fracture in a patient who underwent RCA stenting with associated RCA perforation and almost complete thrombosis of the RCA and peristent fibrinoid collection. (hindawi.com)
  • During extended clinical follow-up, 2 patients suffered from very late stent thrombosis showing a high degree of malapposition, protrusion, and coronary evaginations at the time of OCT investigation. (eur.nl)
  • This massive study, sponsored by all the major stent makers, as well as the manufacturers of antiplatelet meds, will enroll 20,000 patients and test them at 12 and 30 months to determine the rates of MACCE (death, heart attack and stroke) stent thrombosis and major bleeding complications. (ptca.org)
  • The short back story here is that when drug-eluting stents first came on the market in 2003-2004, the FDA recommended six months of DAPT to keep the blood from clotting in and around the stent (a.k.a. stent thrombosis). (ptca.org)
  • Within a couple of years, reports surfaced about a small number of patients who suffered late stent thrombosis (six months or more after stenting). (ptca.org)
Restenosis17
  • Patients with diabetes mellitus have more extensive coronary artery disease, more disease progression, and restenosis. (lu.se)
  • The restenosis rate was 50% lower in DES-treated patients RR, 0.50 (95% CI, 0.35-0.70) and was associated with a higher adjusted RR of MI, RR, 5.03 (95% CI, 4.25-5.97). (lu.se)
  • This real-life registry study shows that restenosis was halved by DES in diabetic patients with stable or unstable coronary disease, with similar risk of death or MI up to 4 years compared with BMS. (lu.se)
  • The chief advantage of drug-eluting stents (DES) over bare-metal stents is that they significantly reduce the risk for restenosis. (jwatch.org)
  • Drug-eluting stents (DES) were developed in the early 2000s to reduce restenosis (ie, recurrent narrowing) rates in stented coronary lesions. (medscape.com)
  • [ 2 , 3 ] There was significant improvement in angiographic results (in stent late lumen loss: 0.17 mm vs 1.00 mm) as well as clinical outcomes (binary in-lesion restenosis: 8.9% vs 36.3%) in the sirolimus stent treatment group relative to the BMS group. (medscape.com)
  • [ 4 ] Restenosis remains an issue in coronary drug-eluting stent implantation for ostial RCA lesions. (medscape.com)
  • Follow-up angiography showed no differences in terms of in-stent late loss (0.18 ± 0.54 mm vs. 0.20 ± 0.99 mm, p = 0.76) and in-segment binary restenosis (8.5% vs. 8.5%, p = 0.76). (ox.ac.uk)
  • The study, HORIZONS-AMI (Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction), showed that in heart attack patients undergoing angioplasty, the use of paclitaxel-eluting stents reduces rates of target lesion revascularization (TLR) and binary angiographic restenosis when compared to the use of bare-metal stents after one year. (dotmed.com)
  • The use of paclitaxel-eluting stents also resulted in a significant reduction in binary restenosis after 13 months, which is the rate at which the artery re-narrows at least 50 percent following implantation of the stent, and was the secondary efficacy endpoint of the trial. (dotmed.com)
  • BACKGROUND: In-stent restenosis (ISR) remains one of the main limitations for percutaneous coronary intervention of unprotected distal left main (UDLM). (unisr.it)
  • In 23 lesions, IVL was used for the treatment of in-stent restenosis (ISR). (frontiersin.org)
  • The main objective of this study is to assess the safety, efficacy and dose response of LABR-312 administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent in reducing restenosis as measured by Optical Coherence Tomography (OCT) at 9 months post procedure in patients with diabetes mellitus (DM). (vchri.ca)
  • Administration of LABR-312 at the time of PCI will reduce restenosis compared with placebo as assessed by the OCT endpoint of % neointimal hyperplasia (%NIH) volume at 9 months in patients with DM. (vchri.ca)
  • In-stent restenosis is clinically challenging and accounts for about 10% of all percutaneous coronary interventions. (medscape.com)
  • Furthermore, PCI is associated with certain limitations in diabetics because these patients have a higher risk of restenosis, MI, and cardiac mortality after the procedure. (medicaleconomics.com)
  • Application of genetic risk score for in-stent restenosis of second- and third-generation drug-eluting stents in geriatric patients. (cdc.gov)
Percutaneous15
Lesion9
  • CONCLUSIONS: In this population treated with predominantly new-generation drug-eluting stents, diabetic patients were at increased risk for repeat target-lesion revascularization consistently across the spectrum of disease complexity. (ox.ac.uk)
  • TLR, which was the primary efficacy endpoint of the trial, refers to the rate at which a particular lesion re-narrows following stent implantation severely enough to require either a repeat angioplasty or bypass surgery operation. (dotmed.com)
  • We analysed 9,217 patients who underwent stenting for a single lesion from the GRAND-DES registry, a patient-level pooled registry including five Korean multicentre DES registries. (pcronline.com)
  • Target lesion failure may be more frequent when IVL is performed for the treatment of ISR due to calcium-mediated stent under expansion. (frontiersin.org)
  • The thin-strut stent is designed for improved conformability, minimal recoil, and uniform lesion coverage and drug distribution. (prnewswire.com)
  • In April 2011 , results from an analysis of pooled patient-level data from 2,298 patients enrolled in the PERSEUS and TAXUS ATLAS clinical trials showed that the ION Stent demonstrated significantly lower rates of major adverse cardiac events, target lesion failure and myocardial infarction compared to the TAXUS® Liberte® Paclitaxel-Eluting Stent System. (prnewswire.com)
  • Boston Scientific) was superior to conventional balloon angioplasty in preventing target lesion failure at 1 year in a high-risk patient population. (medscape.com)
  • Methods: A total of 88 event-free patients with 1 randomly selected lesion were suitable for final OCT analysis 5 years after drug-eluting stent implantation. (eur.nl)
  • This lesion was treated with stent placement in the left anterior descending coronary artery, as observed in the right panel. (medscape.com)
Underwent7
  • We performed a prospective cohort study involving a total of 433 patients who underwent successful drug-eluting stent implantation. (ecrjournal.com)
  • A total of 105 consecutive patients with 110 calcified lesions underwent IVL. (frontiersin.org)
  • The goal of the trial was to evaluate oral anticoagulation alone compared with oral anticoagulation plus clopidogrel among patients who underwent transcatheter aortic valve replacement (TAVR) and had a long-term indication for oral anticoagulation. (acc.org)
  • Patients who underwent TAVR and had a long-term indication for oral anticoagulation were randomized to oral anticoagulation alone (n = 164) versus oral anticoagulation plus clopidogrel for 3 months (n = 162). (acc.org)
  • Among patients who underwent TAVR and had an indication for long-term anticoagulation, oral anticoagulation alone was associated with a reduction in all bleeding and procedural bleeding compared with oral anticoagulation plus clopidogrel. (acc.org)
  • Participants 603 976 patients who underwent isolated CABG or PCI in the Spanish National Health System. (bmj.com)
  • In 2003, approximately 84% of the 660,000 hospitalized patients who underwent a coronary angioplasty received a stent, a wire mesh tube inserted during angioplasty to reduce future narrowing of arteries. (cdc.gov)
Revascularization With Drug-Elutin3
  • Impact of Diabetic Status on Outcomes After Revascularization With Drug-Eluting Stents in Relation to Coronary Artery Disease Complexity: Patient-Level Pooled Analysis of 6081 Patients. (ox.ac.uk)
  • Impact of sex on clinical and angiographic outcomes among patients undergoing revascularization with drug-eluting stents. (ox.ac.uk)
  • OBJECTIVES: The goal of this study was to investigate sex-based differences in long-term clinical and angiographic outcomes after coronary revascularization with drug-eluting stents (DES). (ox.ac.uk)
Metal stents9
  • Patients who received at least one DES (n = 4754) were compared with those who received only bare metal stents (BMS) (n = 4956) at the index procedure. (lu.se)
  • Initially, drug-eluting stents (DES) were compared to bare-metal stents (BMS) for efficacy. (medscape.com)
  • Bare metal stents (BMS) were the first stents which were used during PCI [ 7 ]. (biomedcentral.com)
  • New York-Presbyterian Hospital and Columbia University Medical Center, together with the Cardiovascular Research Foundation (CRF), announced that its landmark study comparing the safety and efficacy of drug-eluting stents and bare-metal stents was published in the May 7 New England Journal of Medicine. (dotmed.com)
  • Outcomes from prior registry and randomized trials of drug-eluting stents compared with bare-metal stents in heart attack patients have been conflicting. (dotmed.com)
  • These results now provide definitive evidence that paclitaxel-eluting stents are superior in efficacy to bare-metal stents and have a comparable safety profile at one year," says Dr. Stone. (dotmed.com)
  • The findings from the HORIZONS-AMI trial will have a major impact on how decisions are made regarding drug-eluting and bare-metal stents in the highest-risk patients, those in the early hours of a heart attack. (dotmed.com)
  • The HORIZONS-AMI trial, a prospective, open-label, multicenter, controlled study, enrolled 3,602 heart attack patients at 123 centers in 11 countries, 3,006 of whom were randomized to paclitaxel-eluting stents versus otherwise identical bare-metal stents. (dotmed.com)
  • Drug-eluting stents (DES) were associated with decreased rates of death, myocardial infarction (MI), and revascularization at 3 years of follow up in diabetic patients compared to bare-metal stents (BMS), according to results of a large observational study. (medicaleconomics.com)
Sirolimus-eluti1
  • In a 5-year study of outcomes from the j-CYPHER registry which compared sirolimus-eluting stent treatment in 397 patients with ostial right coronary artery (RCA) lesions with 3716 patients with nonostial RCA lesions, researchers concluded that sirolimus-eluting stent implantation for ostial RCA was associated with a higher risk of target legion revascularization than when used in patients with nonostial RCA lesions. (medscape.com)
Paclitaxel-eluti1
  • The paclitaxel-eluting stent had a rate of 10.0 percent and the bare-metal stent had a rate of 22.9 percent. (dotmed.com)
Stenosis1
  • Diagnosis and outcome of renal function in patients with renal artery stenosis: which role have color Doppler sonography and magnetic resonance angiography? (minervamedica.it)
Diabetic patients5
  • The strategy of CABG is better than PCI for diabetic patients with multivessel CAD. (archivesofmedicalscience.com)
  • Grover and colleagues showed statin therapy in diabetic patients without CAD to be as cost-effective as statin therapy in nondiabetic patients with CAD. (medscape.com)
  • CABG is considered preferable in diabetic patients with multivessel coronary artery disease based primarily on post hoc analysis of the BARI study. (bmj.com)
  • Researchers then identified 5,423 evaluable diabetic patients and excluded 372 who had received both stent types. (medicaleconomics.com)
  • The results show preserved efficacy of DES in diabetic patients, with no increased hazard of death, MI, or revascularization rates. (medicaleconomics.com)
Lesions13
  • These stents are FDA approved for single de novo coronary lesions of limited length within specific diameter size ranges. (medscape.com)
  • [ 1 ] which compared the sirolimus-eluting CYPHER stent with its noncoated counterpart, the BX velocity stent, in 238 patients with de novo lesions less than 18 mm in length in native coronary arteries 2.5-3.5 mm in diameter. (medscape.com)
  • The SIRIUS trial, which included 1058 patients with workhorse lesions who were randomly assigned to either sirolimus-eluting stents or BMS, demonstrated the long-term efficacy and safety of sirolimus-eluting stents. (medscape.com)
  • Even though patients with DM often have more complicated lesions and more severe disease, including more extensive and diffuse atherosclerosis, with increased risk of triple vessel diseases, and left main coronary occlusions, DES was a good option when the patients were candidates for PCI [ 9 ]. (biomedcentral.com)
  • Furthermore, the occurrence of MB-ISR within 1-year was associated with cardiac-death (HR 2.734, p = 0.017).CONCLUSIONS: The patients with MB-ISR had more comorbidities and complex lesions, resulting in higher risk of cardiac mortality as compared to the patients without MB-ISR. (unisr.it)
  • A total of 87 de novo lesions were treated by IVL with the following indications: 25 before attempting other balloon-based devices (primary IVL), 51 after the failure of non-compliant balloon dilatation (secondary IVL), and 11 after stent implantation because of stent under expansion (bailout IVL). (frontiersin.org)
  • This retrospective, observational study included consecutive patients with calcified coronary lesions treated with IVL from December 31, 2018 to December 31, 2020 at the Centro Cardiologico Monzino, University of Milan, Italy. (frontiersin.org)
  • The advanced low-profile delivery system facilitates precise delivery of the stent across challenging lesions. (prnewswire.com)
  • Exceptional stent deliverability offers cardiologists the potential to treat patients with difficult-to-reach lesions. (prnewswire.com)
  • The ION Stent has been evaluated in the PERSEUS trial, which reported 12-month results in March 2010 , demonstrating positive safety and efficacy outcomes in workhorse lesions compared to the TAXUS® Express2® Stent System. (prnewswire.com)
  • The recent introduction of drug-eluting stents (DESs), together with advances in periprocedural and postprocedural adjunctive pharmacotherapies, has improved outcomes of PCIs of these lesions. (amrita.edu)
  • Despite improvement in stent technology and operator experience, management can be challenging especially in LMCA bifurcation lesions and, therefore, an integrated approach combining advanced devices, tailored techniques, adjunctive support of physiological evaluation, and adjunctive pharmacological agents should be reinforced to improve clinical outcome. (amrita.edu)
  • Despite an overall low degree of uncovered and malapposed struts in event-free patients, some lesions show a clustering of these characteristics, indicating a heterogeneous healing response, which may be the source for very late adverse events. (eur.nl)
Bare2
  • Few data have been reported so far in patients with diabetes mellitus, which is associated with high rates of target vessel revascularization after bare-metal stent (BMS) implantation but also higher rates of ST after DES implantation. (mssm.edu)
  • Background: The purpose of the present study was to compare the 5-year clinical outcomes after implantation of drug-eluting stent (DES) and bare-metal stent (BMS) in Japanese patients with acute myocardial infarction (AMI). (fujita-hu.ac.jp)
Clopidogrel4
  • Scholars@Duke publication: Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. (duke.edu)
  • OBJECTIVES: In this analysis of 2-year outcomes in the ADAPT-DES (Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents) study, the authors sought to examine the independent associations between platelet reactivity to both aspirin and clopidogrel and subsequent outcomes. (duke.edu)
  • DAPT or clopidogrel plus aspirin) after drug-eluting stent placement. (ptca.org)
  • Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the FRENA registry. (janusinfo.se)
Methods2
  • METHODS: Individual patient data from 3 all-comers randomized DES trials (SIRTAX, LEADERS, RESOLUTE All-Comers) were pooled. (ox.ac.uk)
  • This study aims to demonstrate the impact of main-branch ISR (MB-ISR) on mortality and to clarify the optimal strategy.METHODS: Between 2002 and 2008, 482 consecutive UDLM patients treated with drug eluting stent (sirolimus and paclitaxel) were evaluated.RESULTS: During follow-up period (median 52.6 months), MB-ISR occurred in 29, SB-ISR in 65, and MB/SB-ISR in 24. (unisr.it)
Diabetes9
  • Individual patients' data were obtained from 11 of 13 trials, including a total of 972 patients with diabetes (616 [63.4%] randomized to DES and 356 [36.6%] to BMS). (mssm.edu)
  • Three quarters of all deaths in patients with diabetes are caused by coronary artery disease. (bmj.com)
  • It has been projected that 25-30% of all revascularisations will be in patients with diabetes by 2010. (bmj.com)
  • While some other studies have also performed subgroup analyses in patients with diabetes, in none was that analysis prespecified. (bmj.com)
  • In light of recent developments in the field of revascularisation, with the advent of glycoprotein (GP) IIb/IIIa inhibitors, use of stents, and the development of off bypass and minimally invasive surgery, the data available to guide treatment in patients with diabetes are in need of reassessment. (bmj.com)
  • It has been suggested that there might be a difference in outcome of CABG versus PCI in the subset of patients with diabetes mellitus. (bmj.com)
  • The cohort of 1829 patients in BARI included 353 with diabetes. (bmj.com)
  • Subgroup analyses of the primary outcome in terms of sex, age, diabetes, vessel size, or single or multiple stent layers all trended in favor of AGENT DCB but were not statistically significant for interaction. (medscape.com)
  • Alert FDA Approves New 'Smart' Continuous Glucose Monitor for Diabetes Designed for patients with diabetes who use multiple daily insulin injections, Medtronic's Guardian Connect is the first stand-alone CGM with predictive capability. (medscape.com)
Angioplasty4
  • Fifteen percent of patients needing an angioplasty to treat a heart blockage have severely abnormal levels of arterial calcium that would benefit from this new device. (uspharmacist.com)
  • AGENT IDE was a prospective, multicenter, superiority trial that randomly assigned 480 patients 2:1 to the AGENT DCB (n = 321) or to conventional balloon angioplasty (n = 159). (medscape.com)
  • There was no stent rethrombosis with the DCB vs 3.9% with the conventional balloon angioplasty. (medscape.com)
  • Black and white angioplasty patients were equally likely to receive a stent. (cdc.gov)
Dual-antiplatelet therapy3
  • Patients (n = 120) receiving anticoagulation therapy at 12-months post PCI were classified into the following groups according to antiplatelet therapy status: no antiplatelet therapy (n = 16), single antiplatelet therapy (SAPT) (n = 85), and dual antiplatelet therapy (DAPT) (n = 19). (nih.gov)
  • 46.3% of patients were on dual antiplatelet therapy at 2 years without discontinuation. (duke.edu)
  • Background and objectives We aimed to investigate the benefits and risks of dual antiplatelet therapy (DAPT) after coronary drug-eluting stent (DES) implantation in patients undergoing hemodialysis. (tmu.edu.tw)
Outcome1
  • Patient selection for both the techniques directly impacts clinical outcome. (amrita.edu)
Efficacy6
  • The use of drug-eluting stents (DES) in these patients is widespread, despite uncertain long-term safety and efficacy. (lu.se)
  • This study removes much of the uncertainty and concern about the efficacy and safety of drug-eluting stents in this clinical setting. (dotmed.com)
  • Substantial evidence supports the use of statins in the secondary prevention of CAD, and the efficacy of statins has recently been extended to include primary prevention of CAD in patients with average cholesterol levels. (medscape.com)
  • The ION Stent is backed by the proven safety and efficacy of the TAXUS clinical program, which spans 10 years of research in nearly 50,000 patients in 28 pre- and post-market studies. (prnewswire.com)
  • The PERSEUS data confirmed that the proven TAXUS drug and polymer combination has been successfully transferred to the advanced ION Stent platform with excellent performance and comparable safety and efficacy. (prnewswire.com)
  • Recent studies comparing efficacy and safety of PCIs using drug-eluting stents and CABG revealed comparable results in terms of safety and a lower need for repeat revascularisation for CABG. (amrita.edu)
Myocardial5
  • Myocardial infarction was significantly less common with DES in patients who received only one stent RR, 0.80 (95% CI, 0.66-0.96). (lu.se)
  • Cases of myocardial infarction or death within 1 year after DES implantation were matched one-to-one with control patients. (tmu.edu.tw)
  • A meta-analysis of nearly 5000 patients found that statins administered before invasive procedures significantly reduced the risk for postprocedural myocardial infarction. (medscape.com)
  • Patients with acute myocardial infarction on admission were excluded. (bmj.com)
  • Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. (janusinfo.se)
Placement3
  • It is hence a rare case of stable RCA perforation following stent placement. (hindawi.com)
  • However, the patient had recurrent angina within a month of stent placement. (hindawi.com)
  • Cardiac catheterization was generally followed by interventional or therapeutic procedures to open blocked arteries-e.g., atherectomy, stent placement, grafting, or pacemaker implantation. (uspharmacist.com)
Angiographic1
  • pharmacological stents were implanted in almost all cases, and angiographic and clinical success rates were high. (bvsalud.org)
Versus2
  • In this analysis we aimed to systematically compare the long term (≥ 12 months) adverse cardiovascular outcomes observed in DM versus non-DM patients who were implanted with BP-DES. (biomedcentral.com)
  • Cochrane central, MEDLINE (Subset PubMed), EMBASE, Web of Science, http://www.ClinicalTrials.gov and Google scholar were searched for relevant publications involving BP-DES in patients with DM versus non-DM and their associated adverse cardiovascular outcomes. (biomedcentral.com)
Antiplatelet therapy2
  • Most anticoagulated patients were continued on antiplatelet therapy 12-months post PCI. (nih.gov)
  • The bottom line is that all patients are not the same - and they respond to antiplatelet therapy differently. (ptca.org)
Bioabsorbable1
  • Now, a new drug-eluting, bioabsorbable stent manufactured by Intersect (Palo Alto, Calif.) is being billed as a "breakthrough treatment [that] improves outcomes for sinus surgery," according to a news release from the company. (enttoday.org)
Neointimal hyperplasia1
  • Coronary stents are generally indicated to increase coronary vessel diameter in the setting of ischemia due to coronary blockage, either by a combination of acute recoil, arterial contraction of a previously treated segment, and/or local neointimal hyperplasia. (medscape.com)
CYPHER3
  • A study of first-generation drug-eluting stents in the Journal of the American College of Cardiology shows that first-generation drug-eluting stents, especially Cordis Corp.'s Cypher, are more likely to fracture than previously thought. (massdevice.com)
  • The study provides some welcome good news for BSX's Taxus, which took a beating in recent studies when compared with the Cypher and Abbott 's (ABT) Xience stent. (massdevice.com)
  • He found significant incomplete coverage in the CYPHER and TAXUS stents, but complete healing in the ENDEAVOR. (ptca.org)
TAXUS3
  • This study determined drug-eluting stents outcomes in relation to diabetic status and coronary artery disease complexity as assessed by the Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score. (ox.ac.uk)
  • Outside the U.S., including CE Mark countries where it was approved in May 2010 , the ION Stent System is commercialized as the TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System. (prnewswire.com)
  • TAXUS DES Trials Results: How Long Should Thienopyridine Be Used After Drug Eluting Stent? (audiomedica.com)
Therapy7
  • This study describes changes to antithrombotic therapy and associated outcomes 12-months following PCI in patients requiring ongoing anticoagulation therapy. (nih.gov)
  • Records of patients identified from queries of electronic medical records were manually reviewed to verify changes to antithrombotic therapy from discharge to 12-months and at 12-months following PCI, and episodes of major bleeding, clinically relevant non-major bleeding (CRNMB), major adverse cardiovascular or neurological events (MACNE), and all-cause mortality outcomes during an additional 6-months follow-up. (nih.gov)
  • Bleeding was numerically more common in anticoagulated patients continuing SAPT therapy beyond 12 months. (nih.gov)
  • The patient was stable and put on medical therapy and advised regular followups. (hindawi.com)
  • Conclusion For patients with AMI, early and low-dose pravastatin therapy (10 mg/daily) reduces recurrent major adverse cardiac events, mostly the requirement for revascularization. (go.jp)
  • Nitroglycerin is preferable to morphine , which should be used judiciously (eg, if a patient has a contraindication to nitroglycerin or is in pain despite nitroglycerin therapy). (msdmanuals.com)
  • Impact of CYP2D6 polymorphisms on tamoxifen treatment in patients with retroperitoneal fibrosis: A first step towards tailored therapy? (cdc.gov)
Treatment of coronary1
  • The ION Stent System incorporates a unique platinum chromium (PtCr) alloy designed specifically for coronary stenting and intended to improve the acute performance of coronary stent implantation in the treatment of coronary artery disease. (prnewswire.com)
Acute9
  • The odds of remaining on DAPT at 12-months were higher in patients who had PCI for acute coronary syndrome (odds ratio [OR] 2.91, 95% confidence interval [CI] 0.96, 8.77), and in those experiencing MACNE in the 12-months following PCI (OR 1.95, 95% CI 0.67, 5.66), but these associations were not statistically significant. (nih.gov)
  • ARIAD developed Ponatinib (Iclusig), a tyrosine kinase inhibitor for the treatment of adult patients with Philadelphia chromosome-positive [Ph+] chronic myeloid leukemia (CML), and acute lymphoblastic leukemia. (wikipedia.org)
  • On December 14, 2012 the FDA approved ARIAD's leukemia drug Ponatinib for patients with all forms of Ph+ CML or Ph+ acute lymphoblastic leukemia (ALL) who are resistant to or unable to tolerate other tyrosine kinase inhibitors. (wikipedia.org)
  • Intensive glucose control with insulin in patients with an acute coronary syndrome reduces platelet reactivity during hospitalization, compared to conventional control. (revespcardiol.org)
  • 180 mg/dL), on platelet reactivity after hospital discharge in patients with an acute coronary syndrome and hyperglycemia. (revespcardiol.org)
  • The in-stent RCA was consequently completely occluded with minimal flow in a short segment of post-stent RCA and in its acute marginal branch vessel. (hindawi.com)
  • I look forward to using the ION Stent in my daily practice, and I believe our patients will benefit from its improved acute performance," said Louis Cannon , M.D., FACC, FACA, Heart and Vascular Institute Program Director at Northern Michigan Regional Hospital in Petoskey, MI. (prnewswire.com)
  • The positive clinical data from our PtCr Series trials support the acute performance benefits provided by our new platinum chromium stent platform," said Keith D. Dawkins , M.D., Senior Vice President and Chief Medical Officer for Boston Scientific's Cardiology, Rhythm and Vascular Group. (prnewswire.com)
  • In the early days of the pandemic when information on COVID-19 infection was lacking, all COVID-19 positive patients were admitted into acute hospitals for. (annals.edu.sg)
Intervention1
  • The patient revealed no viable tissue in the RCA territory on cardiac MRI, and hence further intervention to salvage the RCA supply was deferred. (hindawi.com)
Registry1
  • I n a study published in the Archives of Internal Medicine , Amit Amin and colleagues analyzed data from 1.5 million PCI procedures included in the National Cardiovascular Data Registry (NCDR) CathPCI registry to assess whether a higher risk for target vessel revascularization (TVR) is associated with greater DES use and to estimate the economic impact of less DES use in patients who are at low risk for TVR. (jwatch.org)
Optical Coherence1
  • Objectives: This study sought to assess stent strut coverage, malapposition, protrusion, and coronary evaginations as markers of healing 5 years after implantation of sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES), by optical coherence tomography (OCT). Background: Early-generation drug-eluting stents have been shown to delay vascular healing. (eur.nl)
Aspirin1
  • Between years 1 and 2, high platelet reactivity was not associated with the very late ST and in patients on aspirin monotherapy, aspirin hyporesponsiveness was not associated with adverse outcomes. (duke.edu)
Vessel3
  • Finally, the analysis of ten studies involving 5,264 patients showed that patients with CABG had worse baseline characteristics, a higher rate of stable angina pectoris, a higher percentage of triple-vessel disease, higher incidence of chronic total occlusion and a higher SYNTAX score. (archivesofmedicalscience.com)
  • Patients were excluded if they had a recent ST-elevation MI, bifurcation, saphenous vein or arterial graft, or thrombus in the target vessel. (medscape.com)
  • the 2 procedures were equally effective in the treatment of low-risk patients with 3-vessel disease and in low- and intermediate-risk patients with left main CAD. (medscape.com)
Scaffolds1
  • Drug-eluting stents (DES) are balloon-mounted, expandable, slotted tubular or multilink scaffolds constructed of a stainless steel or cobalt chromium matrix. (medscape.com)
Total occlusion1
  • A catheter angiography done at that time revealed total occlusion of the RCA stent, with grade III collaterals. (hindawi.com)
Cardiovascular3
  • However, the relationship between VEGF-C levels and cardiovascular mortality in patients with established coronary artery disease is unknown. (ecrjournal.com)
  • During the follow-up, a total of 23 patients (5.3 %) died from cardiovascular disease. (ecrjournal.com)
  • In conclusion, a low VEGF-C value was independently associated with cardiovascular mortality in patients after drug-eluting stent implantation. (ecrjournal.com)
Commercialization1
  • ARIAD engaged in the discovery, development, and commercialization of medicines for cancer patients. (wikipedia.org)
Mortality2
  • There was also a 3 percent reduction in MI, which occurred in 204 DES patients and 249 BMS patients (P=0.02), and a 3.2 percent reduction in mortality with 258 and 305 patients dying during follow up (P=0.02). (medicaleconomics.com)
  • Primary and secondary outcomes We investigated the volume of procedures nationwide, the changes of the risk profile of patients and in-hospital mortality of both techniques. (bmj.com)
Long-term7
  • BACKGROUND: The relationship between platelet reactivity and long-term adverse events following implantation of drug-eluting stents (DES) has been incompletely characterized. (duke.edu)
  • Conclusions: In this long-term follow-up analysis of DES compared to BMS in Japanese patients with AMI, there was no significant difference in the incidence of MACE. (fujita-hu.ac.jp)
  • Moreover, all of the patients in this trial will be followed long-term to ensure that these favorable results are maintained. (dotmed.com)
  • How often are goals of care (GOC) discussed during hospitalization of long-term care residents, and what patient characteristics make this more. (the-hospitalist.org)
  • However, the effect of strict, long-term glucose control on platelet reactivity in these patients remains uncertain. (revespcardiol.org)
  • Multiple long-term risks are also associated with drug eluting stents. (hindawi.com)
  • After PCI, patients returned to work an average of five weeks earlier than those undergoing CABG, and there was no difference in long term employment status. (bmj.com)
Trials5
  • Medinol has completed two registrational trials in patients with coronary artery disease, which met its primary and secondary endpoints. (wikipedia.org)
  • Large, multicenter randomized trials of various pharmacologic modalities have recently achieved great success in the treatment of patients with coronary artery atherosclerosis. (medscape.com)
  • Several trials have compared an initial treatment strategy of PCI with a strategy of CABG in patients with multivessel coronary disease. (bmj.com)
  • The PERSEUS clinical program compared the ION Stent to prior-generation Boston Scientific stents in more than 1,600 patients in two parallel trials at 90 centers worldwide. (prnewswire.com)
  • Current treatment guidelines are based principally on consensus opinion and intuition rather than hard evidence that extending DAPT reduces the risk of late and very late ST. In fact, in more recent trials, patients experiencing very late ST are more commonly on DAPT than off. (ptca.org)
Malapposition1
  • Conclusions: Early-generation drug-eluting stents show a similar degree of strut coverage and malapposition at 5 years of follow-up. (eur.nl)
Randomly assigned to either1
  • The patients were randomly assigned to either receive pravastatin (10 mg/daily, n=176) or not (n=177). (go.jp)
Results3
  • This drug reported results of its registration trial at ASCO, June 6, 2016, with encouraging results, leading to approval in the U.S. in April 2017. (wikipedia.org)
  • To help validate the observational study results, researchers applied propensity score matching and performed logistic regression to predict DES treatment by 67 patient, procedural, and hospital variables and then analyzed outcomes in 2,952 matched DES and BMS patients with 1,476 in each group. (medicaleconomics.com)
  • Potential harms of cardiac screening include false-positive results causing patients to undergo potentially unnecessary tests and procedures. (medscape.com)